Rentosertib

Swipe left for English 2025年9月17日，上海 —— 英矽智能科技（上海）有限公司、迈威（上海）生物科技股份有限公司（688062.SH）、上海皓元医药股份有限公司（688131.SH）今日正式宣布达成战略合作协议。三方将本着“优势互补、资源共享、协同创新、互利共赢”的合作理念，协力打造覆盖数百靶点的新型ADC化合物库，筛选并推进下一代ADC候选分子，加速创新ADC药物的产业化落地。 英矽智能与迈威生物、皓元医药达成战略合作协议 高效推进ADC药物的创新和开发 此次合作汇聚了ADC药物开发产业链的核心力量，形成了从靶点发现到临床开发的完整创新体系。作为全产业链布局的创新型生物制药公司，迈威生物拥有国际领先的ADC药物开发平台，并已获得临床验证，具备强大的研发实力和商业化潜力。在本次战略合作中，迈威生物将开放数百个针对不同靶点的单抗及多抗组合和自主研发的ADC技术平台，覆盖肿瘤、自身免疫等多个疾病领域，为合作提供了行业领先的技术平台支撑。 英矽智能作为全球领先的AI驱动药物研发企业，将运用其Pharma.AI平台在分析疾病机制、靶点特性及毒理结构基础上，设计结构新颖、选择性强的创新payload-linker。该平台已在全球首款AI设计药物开发中得到充分验证，展现了AI技术在药物研发中的巨大优势。 皓元医药作为小分子药物研发服务领军企业，将提供丰富的分子砌块和工具化合物资源库，为ADC药物的linker payload合成提供强有力的技术支撑，与另外两方合作伙伴实现从筛选到临床开发的全流程协同和服务。 此次三方战略合作的达成，是中国生物医药产业在ADC药物领域的创新突破。合作将AI技术与传统药物研发深度融合，开创了ADC药物开发的全新模式，能够在分子设计阶段就预测药物的成药性和安全性，将传统需要数年时间的分子优化过程大幅缩短，显著提升研发效率。三方合作实现了从AI设计、抗体开发、Payload-linker化学合成到临床开发的全产业链协同，构建了ADC药物开发的完整价值链闭环，这种协同模式将最大化发挥各方优势，高效高质推动ADC的创新和发展，为全球患者提供更多治疗选择。 英矽智能联合首席执行官兼首席科学官任峰博士表示：“抗体偶联药物（ADC）被誉为‘魔术子弹’，凭借其独特机制和高靶向性在肿瘤治疗领域展现出巨大潜力，也是英矽智能长期关注和重点投入的重要新型疗法赛道之一。此次与迈威生物和皓元医药达成三方合作，我们率先开创了抗体偶联药物研发的ABC (AI + BioTech/BioPharma + CRO/CDMO)新模式，即打通了AI赋能、Biotech/Biopharma驱动与CRO/CDMO落地的全链路深度协同。我们相信，通过这一创新模式，有望持续加速ADC药物的研发进程，推动更安全、更有效的治疗选择尽早惠及全球患者。” 迈威生物董事长、CEO刘大涛博士表示：“此次合作展现了迈威生物在ADC药物领域的创新战略和布局。迈威生物多年来在抗体药物开发领域积累了丰富的资源。通过与AI技术领先的英矽智能和化学合成实力雄厚的皓元医药强强联合，我们将能够更好地发挥各自优势，加速创新ADC药物的开发进程。我们的目标是打造覆盖广泛靶点的新型payload化合物库，加速研发临床疗效优异的ADC创新药，为全球癌症患者提供更多、更好的治疗选择。” 皓元医药CEO郑保富博士表示：“此次战略合作，是ADC药物研发领域的一次创新举措。皓元医药凭借在ADC Payload-linker领域的深厚积累，携手迈威生物卓越的抗体技术平台与英矽智能前沿的AI药物发现能力，将共同加速创新ADC药物的开发。我们致力于通过高效的资源整合与技术创新，优化候选分子筛选与开发进程，为全球患者提供更快速、更精准的治疗方案。此次合作不仅展现了皓元医药开放共赢的理念，更彰显了我们推动行业进步的决心。未来，我们将持续同合作伙伴们一起探索前沿技术，深化产业协同，为全球创新药发展贡献更多价值。” 关于英矽智能 英矽智能是一家由生成式人工智能驱动的全球先锋生物科技公司，利用其专有的 Pharma.AI 平台和先进的自动化实验室，加速药物发现并推动生命科学领域的创新。通过整合人工智能和自动化技术，英矽智能正在为纤维化、肿瘤学、免疫学、疼痛、肥胖和代谢紊乱等未满足的疾病领域提供创新药物解决方案。英矽智能由人工智能驱动发现的产品管线中，已有10个分子获得临床试验许可，其中进展最为领先的Rentosertib（原名ISM001-055）是一种潜在全球首创用于治疗特发性肺纤维化的候选药物，已完成2a期临床研究并获得令人鼓舞的积极结果。此外，英矽智能还在探索前沿领域，包括老龄化研究、可持续化学和农业创新方面的突破。 更多信息，请访问网站 www.insilico.com 商务合作，请联系 bd@insilico.ai 媒体垂询，请联系 pr@insilico.ai 关于迈威生物 迈威生物 (688062.SH) 是一家全产业链布局的创新型生物制药公司，专注于肿瘤与年龄相关性疾病，始终秉承“让创新从梦想变成现实”的愿景，践行“探索生命，惠及健康”的使命，通过源头创新，为患者提供疗效更好、可及性更强的生物创新药，满足全球未被满足的临床需求。欲了解更多信息，请访问：www.mabwell.com。 关于皓元医药 上海皓元医药股份有限公司（股票代码：688131）成立于2006年，专注于为全球制药和生物医药行业提供小分子、大分子及新分子类型药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司始终将创新作为核心驱动力，以“产品+服务”模式，聚焦差异化发展，致力于打造覆盖药物研发及生产“起始物料 - 中间体 - 原料药 - 制剂”的一体化服务平台，加速赋能全球合作伙伴实现从临床前到商业化生产的全过程，让药物研发更高效，更快上市，更早惠及人类健康。欲了解更多信息，请访问www.chemexpress.com。 右滑查看中文版 Shanghai, September 17, 2025 — Insilico Medicine, Mabwell Bioscience (688062.SH), and ChemExpress (688131.SH) officially announced the signing of a strategic cooperation agreement. The partnership is founded on the principles of complementary strengths, resource sharing, collaborative innovation, and mutual trust. The three parties will jointly develop a novel ADC compound library covering hundreds of targets, screen and advance next-generation ADC candidate molecules, and accelerate the industrialization of innovative ADCs. Insilico Medicine, Mabwell Bioscience, and ChemExpress Forging Ahead with ADC Innovation Through Strategic Collaboration This collaboration unites core competencies across the ADC development value chain, establishing a comprehensive innovation system from target discovery to clinical development. As an innovative biopharmaceutical company with end-to-end capabilities, Mabwell owns clinically validated, industry-leading ADC development platform, demonstrating strong research and development (R&D) capabilities and commercialization potential. Mabwell will contribute industry-leading technical support for the collaboration by providing access to its proprietary ADC technology platform, as well as hundreds of monoclonal antibodies and multi-specific antibodies for diverse targets targeting diverse therapeutic areas including oncology and autoimmune diseases. Insilico Medicine, a global leading biotechnology company powered by generative AI, will leverage its Pharma.AI platform to design novel payload-linkers with innovative structures and high selectivity, based on analyses of disease mechanisms, target characteristics, and toxicological structures. The platform has been thoroughly validated during the development of Rentosertib, the world's first AI-designed drug, which demonstrated the significant advantages of AI technology in drug discovery. As a global reliable CRO&CDMO partner, ChemExpress is committed to offering an extensive library of molecular building blocks and reference compounds, along with robust technical support for linker payload synthesis. In collaboration with Mabwell Bioscience and Insilico Medicine, ChemExpress will deliver comprehensive, end-to-end services spanning drug discovery, clinical development, and commercialization. The strategic partnership is an innovative breakthrough for the biopharmaceutical industry in China’s ADC field. It combines AI technology with traditional drug development to pioneer a new model of ADC development, which enables the prediction of drug potency and safety at the molecular design stage, shortening the time required for molecular optimization, a process that traditionally takes several years, and greatly enhances R&D efficiency. The collaboration achieves synergy across the entire value chain from AI-driven design and antibody development to payload-linker chemical synthesis and clinical development, establishing a complete, closed-loop value chain for ADC development, and maximizes the advantage of all parties, driving innovation and development of ADCs efficiently and effectively to provide more treatment options for patients worldwide. "Antibody-drug conjugates (ADCs), known as ‘magic bullets’, demonstrate tremendous potential in cancer therapy, based on unique mechanisms and high targeting specificity. ADCs are among the novel therapeutic areas that Insilico Medicine has long focused on and invested in," said Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine. "Through our three-way collaboration with Mabwell and ChemExpress, we have pioneered a new ‘ABC’ (AI+BioTech/BioPharma+ CRO/CDMO) model for ADC drug development—integrating AI power, Biotech/Biopharma drive, and CRO/CDMO implementation to form a deep synergy across the value chain. We believe the innovative model will keep accelerating ADC drug development, allowing safer and more effective treatment options to benefit patients worldwide even earlier." Dr. Liu Datao, chairman of the board and CEO of Mabwell, stated, "This collaboration demonstrates our innovation strategy in the field of ADC. Over the years, Mabwell has accumulated extensive resources in developing antibodies. The collaboration with Insilico, a leader in AI technology, and ChemExpress, a leader in chemical synthesis will enable us to accelerate the development of innovative ADCs with our respective strengths. Our goal is to establish a novel, broad payload compound library targeting a broad spectrum of targets, accelerating the development of ADCs with superior clinical efficacy. Ultimately, we aim to deliver more effective treatment options to cancer patients worldwide." Dr. Baofu Zheng, CEO of ChemExpress, commented, " This strategic collaboration marks an important step forward in ADC drug development. By integrating ChemExpress’s expertise in payload-linker chemistry with Mabwell’s antibody platform and Insilico’s cutting-edge AI drug discovery capabilities, we will accelerate the development of innovative ADCs. Through efficient resource integration and technological innovation, we aim to optimize candidate discovery and development, delivering faster and more precise therapeutic solutions for patients worldwide. This partnership not only reflects ChemExpress’s open and collaborative philosophy, but also demonstrates our commitment to driving industry progress. We will continue to work closely with our partners to explore frontier technologies, strengthen industry collaboration, and create greater value for global drug innovation." About Insilico Medicine Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com About Mabwell Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en. About ChemExpress Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and new modalities such as ADCs/XDCs, peptides and PROTACs. Our comprehensive platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. We support our clients' projects from early drug discovery, process development to commercialization. Over the past 19 years, we have established a state-of-the-art QC/QA system aligning with ICH guidelines for pharmaceutical manufacturing. We provide our clients with high-quality products and CMC services across the entire life-cycle of drug development. For more information, please visit: www.chemexpress.com